Ganymed is dedicated in developing predictive biomarkers that support and complement new therapeutic concepts in cancer treatment and hold the promise for personalized medicine.

ClaudetectTM18.2 is the first and only CE marked in vitro diagnostic (IVD) test which allows to assess the expression levels of Claudin-18.2 (CLDN18.2) in gastroesophageal, pancreatic, lung, and other solid tumors.

CLDN18.2 is a tight junction protein responsible in regulating paracellular permeability by sealing the space between the epithelial and endothelial cellular sheet. It is expressed on differentiated stomach cells only and has not been detected in any other healthy tissue. CLDN18.2 expression has, however, been observed in up to 80% of gastrointestinal adenocarcinomas, 60% pancreatic tumours as well as in other various solid tumors. ClaudetectTM18.2 is a semi-quantitative immunohistochemical assay that selectively and exclusively determines CLDN18.2 protein expression in formalin-fixed, paraffin-embedded cancer tissue in particular from patients with adenocarcinoma of the stomach, gastroesophageal junction, and pancreas as well as for bile duct and lung cancer.

ClaudetectTM18.2 is currently being used in all ongoing clinical studies of IMAB362 with the aim of clinically validating ClaudetectTM18.2 as a companion diagnostic test to assist oncologists in identifying patients who will profit the most from IMAB362 therapy.

For inquiries related to ClaudetectTM18.2, please contact Ganymed at